Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Prolia Bags Favorable Draft Appraisal From UK Medicines Watchdog

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE considers denosumab a cost-effective use of NHS resources for second-line osteoporosis use.

You may also be interested in...



GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 1 Of 2)

GSK's Senior VP Asia Pacific, Japan, and Emerging Markets R&D has been busy pitching the company's established presence in emerging markets to companies looking to expand beyond traditional markets, and even some that aren't.

GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 1 Of 2)

GSK's Senior VP Asia Pacific, Japan, and Emerging Markets R&D has been busy pitching the company's established presence in emerging markets to companies looking to expand beyond traditional markets, and even some that aren't.

GSK's Sandy Macrae On R&D For Emerging Markets: An Interview With PharmAsia News (Part 1 Of 2)

GlaxoSmithKline R&D Chairman Moncef Slaoui tasked Sandy Macrae in 2008 to put together a group that would make sure GSK focused some of its R&D efforts on the needs of Asia Pacific and emerging markets.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel